A Randomized, Double-Blind,Placebo-Controlled, Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of Subcutaneously Administered REGN727 in Healthy Volunteers
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 32
- 主要终点
- The incidence of treatment-emergent adverse events in subjects treated with REGN727 or placebo, reported from the administration of study drug on day 1 to the completion of the study on day 106
研究概览
简要总结
This study will test the safety and tolerability (how the body reacts to the drug) of REGN727 compared with placebo (an inactive substance that contains no medicine) in healthy subjects. The study drug and placebo will be administered by an injection under the skin at one clinic visit. There will be 14 clinic visits, which will include 4 overnight stays. Subjects will be monitored by the study staff for side effects and the body's response to the study drug. Vital signs (blood pressure, temperature, breathing and heart rate) will be checked, and blood and urine samples will be collected at some or all visits.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female 18 to 65 years of age.
- •Weight> 50 kg and <95 kg inclusive
- •For women of childbearing potential, a negative serum pregnancy test at the screening visit and a negative urine pregnancy test on day
- •For men and women of childbearing potential, willingness to utilize adequate contraception and not become pregnant (or have their partner[s] become pregnant during the full duration of the study.
- •Willing, committed, and able to return for all clinic visits and complete all study-related procedures.
- •Able to read, understand and willing to sign the informed consent form.
排除标准
- •Initiation of a new exercise routine or major change to a previous exercise routine within 4 weeks prior to screening visit.
- •Pregnant or breast-feeding females.
- •Significant concomitant illness or history of significant illness such as cardiac, renal, neurological, endocrinological, metabolic or lymphatic disease, or any other illness or condition that would adversely affect the subject's participation in this study.
- •Hospitalization for any reason within 60 days of screening.
- •Known history of Human Immunodeficiency Virus (HIV) antibody; and/or positive Hepatitis B surface antigen, and/or positive Hepatitis C antibody at the screening visit.
- •Previous exposure to any therapeutic or investigational biological agent.
- •History of alcohol or substance abuse within previous 5 years.
研究组 & 干预措施
Cohort 1
Dose 1 versus placebo
干预措施: REGN727 (Drug)
Cohort 1
Dose 1 versus placebo
干预措施: Placebo (Drug)
Cohort 2
Dose 2 versus placebo
干预措施: REGN727 (Drug)
Cohort 2
Dose 2 versus placebo
干预措施: Placebo (Drug)
Cohort 3
Dose 3 versus placebo
干预措施: REGN727 (Drug)
Cohort 3
Dose 3 versus placebo
干预措施: Placebo (Drug)
Cohort 4
Dose 4 versus placebo
干预措施: REGN727 (Drug)
Cohort 4
Dose 4 versus placebo
干预措施: Placebo (Drug)
结局指标
主要结局
The incidence of treatment-emergent adverse events in subjects treated with REGN727 or placebo, reported from the administration of study drug on day 1 to the completion of the study on day 106
时间窗: 106 days
次要结局
未报告次要终点